Corbus Pharmaceuticals, Inc. (CRBP) Upgraded by Zacks to OUTPERFORM
Zacks Investment Research upgraded shares of Corbus Pharmaceuticals, Inc. (CRBP) from N/A to OUTPERFORM on January 07, 2015, with a target price of $6.00. We are initiating coverage of Corbus Pharmaceuticals, Inc […]